Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 6
Submit an article Journal homepage
526
Views
2
CrossRef citations to date
0
Altmetric
Letter to the Editor

Chemotherapy-free, triple combination of obinutuzumab, venetoclax and idasanutlin: antitumor activity in xenograft models of non-Hodgkin lymphoma

Frank HertingRoche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Munich, Germany; View further author information
,
Thomas FriessRoche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Munich, Germany; View further author information
,
Pablo UmañaRoche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Zurich, Switzerland; View further author information
,
Steven MiddletonRoche Pharmaceutical Research and Early Development, Roche Innovation Center New York, New York, USAView further author information
&
Christian KleinRoche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Zurich, Switzerland; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0001-7594-7280View further author information
ORCID Icon
Pages 1482-1485 | Received 03 Apr 2017, Accepted 30 Aug 2017, Published online: 15 Sep 2017
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days
Click to increase image sizeClick to decrease image sizeFree first page

Acknowledgments

This study was sponsored by F. Hoffmann-La Roche Ltd. Medical writing support, under the direction of the authors, was provided by Lucy Carrier and Elizabeth Johnson, Gardiner Caldwell Communications (Macclesfield, UK). Support for third-party writing assistance was provided by F. Hoffmann-La Roche Ltd.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at https://doi.org/10.1080/10428194.2017.1376740.

Additional information

Funding

This study was sponsored by F. Hoffmann-La Roche Ltd. All authors are employees of F. Hoffmann-La Roche Ltd.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.